U.S.

Ozempic supply trackers, bird flu vaccines, and Merck’s future: Pharma news roundup

• Bookmarks: 1

Zepbound injection pen

Eli Lilliy’s sales rose 26% year over year to $8.8 billion in the first quarter of 2024 driven primarily by sales of Mounjaro and Zepbound.
Image: Bloomberg / Contributor (Getty Images)

Pharma giant Eli Lilly said on Friday that it will pile $5.3 billion
into manufacturing its popular weight loss drugs, more than doubling its investment in a manufacturing facility in Lebanon, Indiana. The new spend brings the company’s total investment in the site to a whopping $9 billion, up from its original $3.7 billion commitment — making it now the largest manufacturing investment in the company’s history. 

Advertisement

Read More

This post was originally published on this site

print iconPrint
2 views
bookmark icon